Mendus has reported additional positive data from the Phase Ib ALISON trial in high grade serous ovarian cancer (OC), presented at ASCO 2026. At a median follow-up of 26.4 months, 11 patients had reached the predefined two-year survival follow up, eight were alive and five remained in long-term pro
